CACNA2D3
ENSG00000157445
Target class
Auxiliary transport protein
Chromosome
3
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNA2D3
- Gene name
- Calcium voltage-gated channel auxiliary subunit alpha2delta 3
- Gene symbol
- CACNA2D3
- Protein name
- Voltage-dependent calcium channel subunit alpha-2/delta-3 (Voltage-gated calcium channel subunit alpha-2/delta-3) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-3; Voltage-dependent calcium channel subunit delta-3]
- HSA272268
- alpha2delta-3
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel auxiliary alpha2delta subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 45
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 22.53
- Tissue specificity (Gini)
- 0.539
- Tissue specificity (tau)
- 0.823
- KEGG gene identifiers
- hsa:55799
- Reactome pathways
- R-HSA-112308
- Protein interaction confidence
- 0.828333
- Protein interaction partners
- 21
- End position
- 55074557
- Start position
- 54122427
- Chromosome
- 3
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein .
- Principal piece
- Tissue specificity (tau)
- 0.822987
- Expression inequality (Gini)
- 0.538598
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 22.53
- Brain - Nucleus accumbens (basal ganglia)
- 19.29
- Brain - Cortex
- 17.73
- Brain - Caudate (basal ganglia)
- 14.08
- Heart - Atrial Appendage
- 12.19
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)22.53
- Brain - Nucleus accumbens (basal ganglia)19.29
- Brain - Cortex17.73
- Brain - Caudate (basal ganglia)14.08
- Heart - Atrial Appendage12.19
- Testis11.3
- Brain - Putamen (basal ganglia)10.39
- Brain - Anterior cingulate cortex (BA24)9.2
- Muscle - Skeletal8.07
- Brain - Hypothalamus6.31
- Kidney - Medulla6
- Ovary5.41
- Brain - Hippocampus5.2
- Pituitary5.07
- Heart - Left Ventricle5.05
- Artery - Coronary4.58
- Vagina4.31
- Colon - Sigmoid4.25
- Brain - Amygdala3.92
- Brain - Cerebellum3.86
- Brain - Cerebellar Hemisphere3.82
- Brain - Substantia nigra3.46
- Lung3.2
- Esophagus - Mucosa3.16
- Esophagus - Muscularis3.13
And 29 more, listed on the interactive page.
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker